MeiraGTx is a gene therapy company with end-to-end capabilities in gene therapy discovery, development and GMP manufacturing. The company currently has 6 clinical programs, including one in a pivotal study. In addition, MeiraGTx has two wholly owned GMP manufacturing facilities, a leading proprietary manufacturing platform process, large scale GMP plasmid production as well as in-house fill and finish and QC for stability and release. This infrastructure supports multiple clinical programs from IND through commercialization.

MeiraGTx has also built industry-leading vectorology capabilities including optimization of all viral vector elements, with multiple discovery platforms from de-novo construction thorough AI driven in silico design. MeiraGTx has also developed a transformative riboswitch technology that tightly controls transgene expression in response to bespoke oral small molecules. This technology allows, for the first time, precise control of any transgene in any context based on the dose of a small molecule, which provides enormous potential for expanding the possibilities in genetic medicines today.